Lipsky H
Urologische Abteilung, Landeskrankenhaus Leoben, Osterreich.
Urologe A. 2000 May;39(3):246-50. doi: 10.1007/s001200050349.
For more than 10 years VUR has been treated by endoscopic injections with biocompatible substances. This study presents the results of this procedure with bovine collagen (Zyplast) in 42 children with 66 refluxing ureters. The follow-up period comprises an average time of 6.5 years (2-10 years). In 16 ureters a second and in 4 a third injection was given. In 5 kidneys scarring occurred during the years of follow up. Growth, kidney function and blood pressure remained normal in all children. 6 ureters were reimplanted because of recurrences, in 13 ureters (23%) the reflux improved and since no infection recurred no further management became necessary. In 36 (65.4%) ureters reflux was cured and in further 11 this was supposedly the case. However this was not proven by MCU, because parents refused this investigation. Earlier MCU have shown no reflux. We think that the endoscopic injection with collagen is a excellent option in management of VUR grade I-IV.
十多年来，膀胱输尿管反流（VUR）一直通过内镜注射生物相容性物质进行治疗。本研究展示了对42例患有66条反流输尿管的儿童使用牛胶原蛋白（Zyplast）进行该操作的结果。随访期平均为6.5年（2至10年）。16条输尿管进行了第二次注射，4条输尿管进行了第三次注射。在随访期间，5个肾脏出现了瘢痕形成。所有儿童的生长、肾功能和血压均保持正常。6条输尿管因复发而进行了再植，13条输尿管（23%）的反流有所改善，且由于未再发生感染，无需进一步处理。36条输尿管（65.4%）的反流得到治愈，另有11条输尿管推测也是如此。然而，由于家长拒绝此项检查，排尿性膀胱尿道造影（MCU）未证实这一点。早期的MCU检查未显示反流。我们认为，内镜下注射胶原蛋白是治疗I - IV级VUR的极佳选择。
